Reviewer's report

Title: Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

Version: 2 Date: 9 September 2014

Reviewer: Kohei Shitara

Reviewer's report:

This manuscript reports the efficacy and feasibility of biweekly cetuximab in combination with FOLFOX in phase 2 trial. I think this paper is well written and worth to be published in this journal, although I still have curious about biweekly is really suitable for cetuximab considering T 1/2 of cetuximab. I have just one comment:

Page 8
Treatment exposure
Haematological toxicity leading to chemotherapy delays was the main reason of cetuximab dosing reduction.
> Why author decrease the cetuximab by hematological toxicity? since cetuximab is rarely associated with hematological toxicity

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

No COI